## Law Office of Randall V. Brumbaugh

March 31, 2011

Pink OTC Markets, Inc. 304 Hudson St. 2<sup>nd</sup> Floor New York, NY 10013 FAX TRANSMISSION (212) 652-5920

Re: Opinion Letter re Adequate Current Information of Talisman Holdings, Inc. (TMHO) [fka Chef's Selection, Inc. (CFSC)]

Dear Sir/Madam:

This office has been retained by Talisman Holdings, Inc., (the "Company" or the "Issuer") for the sole purpose of rendering an opinion in connection with the adequacy of the Company's public disclosure documents.

This opinion is solely for the information of the Pink OTC Markets, Inc. ("Pink OTC Markets"). Pink OTC Markets is entitled to rely on this opinion in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933, as amended. This opinion is not to be quoted in whole or in part or otherwise referred to, nor is it to be filed with any governmental agency or other person without my prior written consent, except that Pink OTC Markets has full and complete permission and rights to publish this correspondence through the OTC Disclosure and News Service for viewing by the public and regulators.

This correspondence will serve to verify that I am a U. S. resident and citizen and have been retained solely for the limited purpose of reviewing the current information supplied by the Issuer.

I am licensed to practice law before the United States Supreme Court, the Ninth Circuit Court of Appeals, the Northern District of California, the Eastern District of California, the Central District of California, the Southern District of California, the United States Tax Court, the Military Court of Appeals and all courts in the State of California. This opinion is limited to the federal laws of the United States of America. I do not express any opinion with respect to the Blue Sky or securities laws of any State or other jurisdiction.

I am permitted to practice before the Securities and Exchange Commission and have not been prohibited from practice thereunder.

Pink OTC Markets March 31, 2011 Page Two

Document

In rendering this limited opinion, I have investigated such matters, examined corporate documents and had such discussions with representatives of the Company as I have deemed necessary or appropriate for purposes of providing this opinion. In all such examinations I have assumed that (1) all information contained therein is true and correct, (2) the genuineness of all signatures (both manual and conformed), (3) all documents submitted to me as originals were authentic, true and complete, (4) all documents submitted to me as copies are true and complete copies of the originals thereof, (5) each natural person signing any document reviewed by me had the legal capacity and authority to do so and (6) that each conversation I had with any representative of the Company was accurate and truthful in all material respects. Nothing came to my attention during the course of my investigation that led me to conclude that any documents provided or made available to me were not genuine or authentic or that assertions made to me by representatives of the Company were not true or were lacking in any material respect.

Additionally, for the purposes of rendering this limited opinion, I have assumed that neither the Issuer nor any person or entity associated with the Issuer has engaged in fraud or misrepresentation. Furthermore, I express no opinion as to the validity of any of the assertions, assumptions, form or content of any financial or statistical data contained in any document or filing of the Company.

I have relied on information obtained from public sources, officers, management and/or representatives of the Company, as well as other sources and I have no reason, based on my information and belief, to believe that these sources are not reliable. I know of no facts which would reasonably lead me to conclude that the opinion set forth herein is inaccurate in any material respect.

The Issuer has submitted, and I have reviewed in connection with the preparation of this correspondence, the following information posted to Pink OTC Markets on the dates indicated:

<u>Bootament</u>	<u>Bate I osted</u>
Annual Report for the period ending 12/31/10	March 29, 2011
Quarterly Report for the period ending 9/30/10	November 15, 2010
Quarterly Report for the period ending 6/30/10, Part 1	August 25, 2010
Quarterly Report for the period ending 6/30/10, Part 2	August 25, 2010
Initial Company Information and Disclosure Statement, Part 1	August 24, 2010
Initial Company Information and Disclosure Statement, Part 2	August 24, 2010
Quarterly Report for the period ending 3/31/10	May 18, 2010
Quarterly Report for the period ending 12/31/09	March 3, 2010
Quarterly Report for the period ending 9/30/09	December 9, 2009
Quarterly Report for the period ending 6/30/09	December 9, 2009
Quarterly Report for the period ending 3/31/09	December 9, 2009

Date Posted

After reasonable investigation, I have no reason to believe that, at the time such information was submitted to the Pink OTC Markets News Service, the information contained any untrue statement of material fact or failed to state a material fact necessary in order to make any statement proffered, in light of the circumstances under which it was made, not misleading.

Pink OTC Markets March 31, 2011 Page Three

I assume no obligation to update or supplement this opinion letter to reflect any change in fact or law which may hereafter come to my attention.

I have reviewed the information posted by the Issuer and after reasonable investigation I am of the opinion that the information (i) constitutes "adequate current information" concerning the Issuer and is "publicly available" within the meaning of SEC Rule 144(c)(2) under the Securities Act of 1933, as amended; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Issuer's securities under SEC Rule 15c2-11 of the Securities Exchange Act of 1934, as amended; (iii) complies as to form with the Pink OTC Markets' Guidelines for Providing Adequate Current Information; and (iv) the Information has been posted through the OTC Disclosure and News Service.

This opinion does not alleviate the professional and personal responsibilities of brokers, dealers and investors to conduct their own professional and person due diligence.

David Long, the President and a Director of the Issuer, is responsible for the preparation of the unaudited financial statements contained in the Information. Based on my information and belief, Mr. Long has been a banker, stockbroker, mortgage broker and owner and operator of commercial restaurants. Consequently, Mr. Long is well versed in accounting and general financial matters.

The Company's transfer agent is Holladay Stock Transfer, Inc., 2939 N. 67<sup>th</sup> Place, Suite C, Scottsdale, Arizona 85251 is registered with the SEC under file number 84-1822. I have relied on information provided to me by the transfer agent in the form of a certified shareholders list relating to the issuance of securities to confirm the number of shares outstanding.

I have previously (i) personally conferred with the Issuer's management and a majority of the directors, (ii) reviewed the information published by the Issuer through the OTC Disclosure and News Service, and (iii) discussed the information with management and a majority of the directors of the Issuer.

To the best of my knowledge, after inquiry of the Issuer's management and directors and any 5% holder, neither the Company, nor counsel, is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

Respectfully submitted,

Randall V. Brumbaugh

cc: Talisman Holdings, Inc.